Tenax Therapeutics Reports $15.7 Million Net Loss in Q1 2026, Increases R&D Spending

Tenax Therapeutics, Inc. reported a net loss of $15.7 million for the first quarter of 2026, a 51% increase from the $10.4 million loss recorded in the same period of 2025. The company's total operating expenses rose to $16.6 million, up 46% from $11.3 million year-over-year. This increase was primarily driven by a significant rise in research and development costs, which surged by 103% to $11.5 million, reflecting the ongoing Phase 3 clinical trials for its lead product candidate, levosimendan. General and administrative expenses decreased slightly by 11% to $5.0 million, indicating a focus on managing operational costs amid rising R&D expenditures.

In terms of financial position, Tenax reported total current assets of $123.2 million as of March 31, 2026, compared to $104.2 million at the end of 2025. The increase in cash and cash equivalents to $118.8 million from $97.6 million was bolstered by financing activities, including the exercise of warrants and pre-funded warrants, which generated $30.5 million in cash during the quarter. The company’s accumulated deficit reached $383.2 million, reflecting its ongoing investment in product development without generating revenue.

Strategically, Tenax has been focused on advancing its clinical trials for levosimendan, which is being evaluated for pulmonary hypertension. The company achieved its target enrollment of 230 patients for the LEVEL trial in March 2026 and has also commenced a second global Phase 3 study, LEVEL-2. These trials are critical as Tenax aims to submit marketing authorization applications following their completion. The company has deprioritized the development of imatinib for pulmonary arterial hypertension, redirecting resources to its lead candidate.

Operationally, Tenax has seen an increase in employee headcount, which contributed to higher salary and benefits costs. The company is actively expanding its clinical trial activities, necessitating additional personnel and resources. As of March 31, 2026, Tenax had 24.3 million shares of common stock outstanding, a significant increase from 9.3 million shares at the end of 2025, reflecting the exercise of warrants and pre-funded warrants.

Looking ahead, Tenax management believes that its current cash position, along with additional funds raised from warrant exercises, will be sufficient to support operations through at least the first quarter of 2028. The company continues to evaluate opportunities for additional financing to support its clinical development programs and is focused on achieving milestones that could lead to future revenue generation.